| Literature DB >> 30611297 |
Yandie Li1, Qi Zheng1, Lixia Zou1, Jianqiang Wu1, Li Guo1, Liping Teng1, Rongjun Zheng1, Lawrence Kwok Leung Jung2, Meiping Lu3.
Abstract
BACKGROUND: As an acute febrile and inflammatory disease, Kawasaki disease (KD) could develop Kawasaki disease shock syndrome (KDSS) sometimes. However its pathogenesis was still not well known. This study was to learn more about the clinical features and evaluate the role of cytokines in the pathogenesis of KDSS.Entities:
Keywords: Clinical features; Cytokines; Kawasaki disease; Shock
Mesh:
Substances:
Year: 2019 PMID: 30611297 PMCID: PMC6321686 DOI: 10.1186/s12969-018-0303-4
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Demographic and clinical features of patients with KDSS or KD
| KDSS( | KD( |
| |
|---|---|---|---|
| Age(months), | |||
| Mean ± SD | 43.41 ± 31.42 | 28.81 ± 21.51 | 0.04a |
| Median(range) | 38 (2–102) | 22 (3–89) | 0.048b |
| Female gender, no. (%) | 10(37.0) | 24(55.8) | 0.147c |
| Fever(days),mean ± SD | 10.63 ± 5.12 | 6.98 ± 2.45 | 0.001 c |
| Conjunctivitis, no.(%) | 24(88.90) | 41(95.3) | 0.367 c |
| oral mucous membrane changes, no.(%) | 26(96.3) | 41(95.3) | 0.671 c |
| Cervical lymphadenopathy,no.(%) | 22 (81.5) | 36(83.7) | 0.526 c |
| changes in the peripheral extremity, no.(%) | 21 (77.8) | 35(81.4) | 0.764 c |
| polymorphous rash, no.(%) | 22 (81.5) | 36(83.7) | 0.526 c |
aTwo-sample t test
bManne-Whitney U test
cFisher’s exact test
Comparison of laboratory data of patients with KDSS or KD
| KDSS (n = 27) | KD (n = 43) |
| |
|---|---|---|---|
| WBC count (×109/L) | 19.04 ± 8.53 | 13.12 ± 5.22 | 0.002a |
| PMNs (%) | 79.44 ± 17.56 | 60.76 ± 14.34 | < 0.001 a |
| Hb(g/L) | 99.37 ± 12.69 | 110.44 ± 10.17 | < 0.001 a |
| Platelet count (× 109/L) | 277(57–531) | 355(150–629) | 0.056 a |
| ESR (mm/h) | 101(24–140) | 67(6–135) | 0.041b |
| ESR > 40 mm/h,no(%) | 25(92.59) | 37(86.05) | 0.472c |
| CRP (mg/dl) | 137.15 ± 54.80 | 76.11 ± 50.66 | < 0.001 a |
| Albumin (mmol/L) | 30.12 ± 6.54 | 36.28 ± 3.73 | < 0.001 a |
| Serum sodium concentration (mmol/L) | 132.85 ± 3.73 | 135.62 ± 3.68 | 0.004 a |
| Serum potassium concentration (mmol/L) | 3.38 ± 0.50 | 3.81 ± 0.46 | 0.001 a |
| ALT (U/L) | 53 (12–415) | 18 (10–477) | 0.014b |
| AST (U/L) | 43 (21–472) | 35 (18–448) | 0.080b |
| Lactic acid concentration (mmol/l) | 1.96 ± 0.79 | 2.14 ± 0.81 | 0.372 a |
| Creatinine(μmol/L) | 47.5(34–456) | 35(25–58) | < 0.001 b |
| BUN(mmol/L) | 5(2–16) | 2.62(1.38–4.84) | < 0.001b |
| CK-MB(U/L) | 34.12 ± 16.05 | 20.01 ± 8.46 | < 0.001a |
| Triglyceride(mmol/L) | 1.78 ± 0.60 | 1.30 ± 0.51 | 0.001 a |
| Blood amylase (U/L) | 54.3(11.9–404.8) | 27.8 (7.1–75.5) | 0.087b |
| Fibrinogen(g/L) | 4(2–7) | 4.46(3.87–5.12) | 0.875b |
| D-dimer(mg/L) | 3.45(1.13–7.88) | 1.16(0.36–1.43) | 0.001b |
| PCT(ng/ml) | 2.33(0.46–19) | 0.56(0.001–21.88) | < 0.001b |
aTwo-sample t test
bManne-Whitney U test
cFisher’s exact test
Serum cytokine levels in patients with KDSS or KD
| Cytokine(pg/ml) | KDSS (n = 27) | KD (n = 43) |
|
|---|---|---|---|
| IL-2 | 4.2 (2.2–28.6) | 4.1 (2–6) | 0.947b |
| IL-4 | 3.2 (1.9–19.4) | 3.9 (1.8–12) | 0.168 b |
| IL-6 | 184.1 (27.7–2577.3) | 54.1 (4–425) | < 0.001b |
| IL-10 | 42.6 (5–236.7) | 9.4 (3–94) | < 0.001b |
| TNF-ɑ | 2.6 (1.0–23.4) | 2.1 (1–6) | 0.029b |
| IFN-γ | 18.3 (4.5–94.4) | 6.7 (2–56) | < 0.001b |
bManne-Whitney U test
Fig. 1ROC curves of IL-2, IL-4, IL-6, IL-10, TNF-α, and IFN-γ between KD and KDSS. The diagonal line is the reference line
Comparison of treatment and outcome of patients with KDSS and KD
| Outcome | KDSS (n = 27) | KD ( |
|
|---|---|---|---|
| Hospitalized duration (days) | |||
| mean ± SD | 13.52 ± 5.12 | 5.35 ± 2.02 | < 0.001a |
| median(range) | 12(8-35) | 5(3–15) | < 0.001b |
| CAAs, no(%) | 15(55.56) | 4(9.30) | < 0.001c |
| Aseptic meningitis, no. (%) | 13(48.15) | 2(4.65) | < 0.001 c |
| Ejection fraction, %,(mean ± SD) | 0.61 ± 0.07 | 0.64 ± 0.05 | 0.159 c |
| ECG abnormality,no.(%) | 18 (66.67) | 2(4.65) | 0.001 c |
| IVIG-resistance,no.(%) | 19 (70.37) | 1(2.30) | 0.001 c |
| Second dose of IVIG,no(%) | 10 (37.04) | 2(4.65) | 0.002 c |
| ICU, no.(%) | 13 (48.15) | 0(0.00) | < 0.001 c |
| vasopressor,no.(%) | 8 (29.63) | 0(0.00) | < 0.001 c |
| Other organ damage,no. (%) | 23 (85.19) | 6(14.00) | 0.001 c |
| KD recurrence,no. (%) | 2(7.41) | 1 (2.3) | 0.555c |
| Incomplete KD,no. (%) | 8(29.62) | 2(4.65) | 0.010c |
| Death, no. (%) | 0 (0.00) | 0 (0.00) | 1.000 c |
aTwo-sample t test
bManne-Whitney U test
cFisher’s exact test